LUPIN LIMITED

SAFETY DATA SHEET

Section 1: Identification

Section 1, Identification

Material Penicillamine Tablets, USP (Titratable Tablets)

Manufacturer Lupin Limited

Nagpur 441 108

INDIA

Distributor Lupin Pharmaceuticals, Inc.

111 South Calvert Street, Harborplace Tower, 21st Floor, Baltimore, Maryland 21202

United States

Tel. 001-410-576-2000 Fax. 001-410-576-2221

Section 2: Hazard(s) Identification

Section 2, Hazard(s) identification

Fire and Explosion Expected to be non-combustible.

Health Except for treatment of Wilson's disease or certain cases of

cystinuria, use of penicillamine during pregnancy is contraindicated.

Although breast milk studies have not been reported in animals or humans, mothers on therapy with penicillamine should not nurse their

infants.

Patients with a history of penicillamine-related aplastic anemia or agranulocytosis should not be restarted on penicillamine. Because of its potential for causing renal damage, penicillamine should not be administered to rheumatoid arthritis patients with a history or other

evidence of renal insufficiency.

Environment No information is available about the potential of this product to

produce adverse environmental effects.

Section 3: Composition/Information on Ingredients

Section 3, Composition/information on ingredients

IngredientsCASPenicillamine USP52-67-5

Section 4: First-Aid Measures

Section 4, First-aid measures

Ingestion If conscious, give water to drink and induce vomiting. Do not attempt

to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water.

SDS : 217/00 Page 1 of 4

Effective Date: 23/12/2019

Obtain medical attention.

Inhalation Move individual to fresh air. Obtain medical attention if breathing

difficulty occurs. If not breathing, provide artificial respiration

assistance.

Skin Contact Remove contaminated clothing and flush exposed area with large

amounts of water. Wash all exposed areas of skin with plenty of soap

and water. Obtain medical attention if skin reaction occurs.

Eye Contact Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment Treat according to locally accepted protocols. For additional guidance,

refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.

Section 5: Fire-Fighting Measures

Section 5, Fire-fighting measures

Fire and Explosion Hazards Assume that this product is capable of sustaining combustion.

Extinguishing Media Water spray, carbon dioxide, dry chemical powder or appropriate

foam.

Special Firefighting Procedures For single units (packages): No special requirements needed.

For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for

firefighters.

Hazardous Combustion Products Hazardous combustion or decomposition products are expected when

the product is exposed to fire.

Section 6: Accidental Release Measures

Section 6, Accidental release measures

Personal Precautions Wear protective clothing and equipment consistent with the degree of

hazard.

Environmental Precautions For large spills, take precautions to prevent entry into waterways,

sewers, or surface drainage systems.

Clean-up Methods Collect and place it in a suitable, properly labeled container for

recovery or disposal.

Section 7: Handling and Storage

Section 7, Handling and storage

Handling No special control measures required for the normal handling of this

product.

SDS : 217/00 Page 2 of 4

Effective Date: 23/12/2019

Normal room ventilation is expected to be adequate for routine

handling of this product.

Storage Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Protect from moisture. Dispense in a tight container.

Section 8: Exposure Controls/Personal Protection

Section 8, Exposure controls/personal protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

Section 9: Physical and Chemical Properties

Section 9, Physical and Chemical Properties

Physical Form

Penicillamine tablets, USP (Titratable Tablets) are white colored, oval shaped, film coated tablets with single score line on both sides. On one side, tablets are debossed with "LU" on left and "L17" on right side of the score line and plain on other side.

Bottles of 100 Tablets NDC 70748-153-01

Section 10: Stability and Reactivity

Section 10, Stability and reactivity

Stable under recommended storage conditions.

Section 11: Toxicological Information

Section 11, Toxicological information

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term animal carcinogenicity studies have not been done with penicillamine. There is a report that five of ten autoimmune disease-prone NZB hybrid mice developed lymphocytic leukemia after 6 months' intraperitoneal treatment with a dose of 400 mg/kg penicillamine 5 days per week.

Section 12: Ecological Information

Section 12: Ecological Information

No relevant studies identified.

Section 13: Disposal Considerations

Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

SDS : 217/00 Page 3 of 4

Effective Date: 23/12/2019

Section 14: Transport Information

Section 14: Transport Information

IATA/ICAO - Not Regulated

IATA Proper shipping Name : N/A
IATA UN/ID No : N/A
IATA Hazard Class : N/A
IATA Packaging Group : N/A
IATA Label : N/A

IMDG - Not Regulated

IMDG Proper shipping Name:N/AIMDG UN/ID No:N/AIMDG Hazard Class:N/AIMDG Flash Point:N/AIMDG Label:N/A

DOT - Not Regulated

DOT Proper shipping Name : N/A
DOT UN/ID No : N/A
DOT Hazard Class : N/A
DOT Flash Point : N/A
DOT Packing Group : N/A
DOT Label : N/A

Section 15: Regulatory Information

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.

SDS : 217/00 Page 4 of 4